Blueprint Medicines — Technical Presentation (June 2017)
19 slides from Blueprint Medicines's technical presentation, Jun 6, 2017
Slide 1: GIST: imatinib and beyond – Clinical activity of BLU-285 in advanced GIST
GIST: imatinib and beyond Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich1, Robin Jones2, Margaret von Mehren3, Patrick Schoffski4, Sebastian Bauer5, Olivier Mir6, Philippe Cassier7, Ferry Eskens8, Hongliang Shi9, Terri Alvarez-Diez9, Oleg Schmidt-Kitt
Slide 2: Disclosures
Disclosures BLU-285 is an investigational agent currently in development by Blueprint Medicines Corporation (Blueprint Medicines) Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing Phase 1 studies in unresectable gastrointestinal stromal tumor Dr. Michael Heinrich has the follo
Slide 3: Imatinib revolutionized Gastrointestinal Stromal Tumor (GIST) treatment
Imatinib revolutionized Gastrointestinal Stromal Tumor (GIST) treatment Imatinib binds the inactive kinase conformation and inhibits many primary mutants Imatinib is a highly effective first-line GIST therapy A-loop imatinib A-loop imatinib Inactive conformation Active conformation KIT KIT mutations
Slide 4: Beyond imatinib, there are no highly effective therapies
Beyond imatinib, there are no highly effective therapies1–6 Primary resistance Secondary resistance 3L regorafenib 1L imatinib 2L sunitinib ORR ~60% PFS 19 mo ORR ~7% PFS 6 mo 4L no approved therapy ORR ~5% PFS 4.8 mo ORR ~0% PFS ≤1.8 mo* 4 Prevalence7,8 Resistance mutation Primary Secondary PDGFRα
Slide 5: BLU-285: highly potent and selective targeting of KIT/PDGFR GIST mutants
BLU-285: highly potent and selective targeting of KIT/PDGFR GIST mutants 5 High kinome selectivity* Binds active conformation BLU-285 *Image reproduced courtesy of CSTI (www.cellsignal.com)
Slide 6: BLU-285: highly active against imatinib-resistant GIST patient derived xenografts
KIT exon 11/17 mutant KIT exon 11/13 mutant BLU-285: highly active against imatinib-resistant GIST patient derived xenografts Tumor regression at 10 and 30 mg/kg QD Tumor regression at 30 mg/kg QD 6
Slide 7: BLU-285 Phase 1 study
BLU-285 Phase 1 study Advanced GIST MTD Part 2 Dose expansion enrolling Unresectable GIST after imatinib and ≥1 other TKI (n=50) PDGFR D842V-mutant GIST (n=50) Part 1 Dose escalation completed Key objectives Part 1: MTD, safety, pharmacokinetics, ctDNA analyses, anti-tumor activity Part 2: response
Slide 8: Demography and baseline patient characteristics
Demography and baseline patient characteristics Parameter All patients, N=72 Age (years), median (range) 61 (25–85) n (%) GIST subtype KIT mutant PDGFR mutant 40 (56) 32 (44) Metastatic disease 69 (96) Largest target lesion size (cm) ≤5 >5–≤10 >10 18 (25) 25 (35) 29 (40) No. prior kinase inhibitors
Slide 9: BLU-285 pharmacokinetics support QD dosing and broad mutational coverage
BLU-285 pharmacokinetics support QD dosing and broad mutational coverage Relatively rapid absorption Tmax ~2–8 hours and long half-life >24 hours Exposure at the 300 and 400 (MTD) mg provides broad coverage of primary and secondary KIT/PDGFR mutations based on patient derived xenografts (PDX) 9 *in
Slide 10: Radiographic response per RECIST 1.1 in PDGFR D842V-mutant GIST
Radiographic response per RECIST 1.1 in PDGFR D842V-mutant GIST Ongoing at cycle 5 Prior imatinib and sunitinib Confirmed PR, -63% target sum Ongoing at cycle 3 Prior imatinib PR (pending confirmation), -85% target sum Target lesion resolution Baseline After 4 months BLU-285 300 mg (dose escalation
Slide 11: Tumor regression across all dose levels in PDGFR D842-mutant GIST
Tumor regression across all dose levels in PDGFR D842-mutant GIST (central radiology review) 11
Slide 12: High response rate and prolonged PFS in PDGFR D842-mutant GIST
High response rate and prolonged PFS in PDGFR D842-mutant GIST Best response (N=25) Choi Criteria n (%) RECIST 1.1 n (%) PR 25 (100%) 15* (60%) SD 0 10 (40%) DCR (PR + SD) 25 (100%) 25 (100%) PD 0 0 Central radiographic review Approved agents are ineffective1,2 ORR ~0% * 12 confirmed, 3 pending con
Slide 13: Radiographic response in heavily pre-treated KIT-mutant GIST
Radiographic response in heavily pre-treated KIT-mutant GIST Ongoing at cycle 12 6 prior TKIs; exon 11, 13, and 18 mutations CHOI PR (density -53%); RECIST SD (-21%) Screening Cycle 3 Cycle 5 Cycle 7 Ongoing at cycle 4 5 prior TKIs; 1 exon 11 mutation; ctDNA pending CHOI PR (density -76%); RECIST P
Slide 14: Dose-dependent tumor reduction across multiple KIT genotypes
Dose-dependent tumor reduction across multiple KIT genotypes (central radiographic review) 14 *ctDNA results pending **per archival tumor and ctDNA
Slide 15: Important clinical activity in heavily pre-treated KIT-mutant GIST
Important clinical activity in heavily pre-treated KIT-mutant GIST Beyond third-line regorafenib there are no approved therapies Imatinib re-treatment in ≥third-line GIST3 ORR ~0% Central radiographic review * 1 confirmed, 1 pending confirmation ↑ PFS with BLU-285 ≥300 mg Best response (N=25) Choi C
Slide 16: Adverse events (AE) associated with BLU-285
Adverse events (AE) associated with BLU-285 18 (25%) patients had Grade (G) ≥3 treatment-related (Fatigue [8%], hypophosphatemia [6%], anemia [4%], nausea, vomiting, hyperbilirubinemia [3% each]) DLT in 2 patients at 600 mg: 1 G2 hyperbilirubinemia; 1 G2 rash, hypertension, memory impairment BLU-285
Slide 17: Conclusions
Conclusions BLU-285 is well tolerated on a QD schedule at doses up to the MTD of 400 mg Exposure at 300–400 mg QD provides broad coverage of primary and secondary KIT / PDGFR mutants BLU-285 has strong clinical activity in PDGFR D842-mutant GIST with an ORR of 60% per central review and median PFS
Slide 18: Acknowledgments
Acknowledgments We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: Oregon Health & Sciences University Royal Marsden Hospital/Institute for Cancer Research Leuven Cancer Institute University of Essen Fox Chase Can
Slide 19: References
References Cassier et al. Clin Cancer Res. 2012;18(16):4458–64 Yoo et al. Cancer Res Treat. 2016;48(2):546–52 Kang et al. Lancet Oncol. 2013;14(12):1175–82 National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors. 2016 Demetri et al. Lancet. 2006;368:1329 Demetri et al. Lancet. 2013;38
Blueprint Medicines — Technical Presentation (June 2017) on 6ix